The fact that this AMPLIFY trial is for diagnostics and not therapy, I'd assume the entire trial will come to a much quicker conclusion relatively speaking.
What is the rate determining step for the trial?
Presumably lesions identified by the imaging requires follow up biopsies - is that what will take all the time?
Its an unfortunate fact that this BCR cohort is relatively large (and thus the market potential is large for a superior diagnostic imaging agent that is also safe) and thus recruitment should not be an issue.
The fact that this AMPLIFY trial is for diagnostics and not...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.21 |
Change
0.050(2.31%) |
Mkt cap ! $710.1M | |||
| Open | High | Low | Value | Volume |
| $2.15 | $2.29 | $2.13 | $3.253M | 1.474M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 22362 | $2.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.21 | 9888 | 39 |
View Market Depth
| Last trade - 15.13pm 16/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |